Insys Therapeutics Inc. agreed to turn over its main synthetic opioid drug to a new owner in exchange for a cut of future sales from the product, which government officials say helped feed America’s addiction to pain killers.
BTcP Pharma will take over a limited number of debts related to the fentanyl spray, Subsys, but not any “fines, judgments, settlements or other liabilities owed to the Department of Justice or other governmental entity” related to the commercialization of the drug, according to a regulatory filing by Insys.
If the sale is approved by the judge overseeing Insys’ liquidation, any money ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.